AzTrials
AzTrials

Post-stroke AphasiaNCT07700537

Efficacy and Neural Mechanisms of Transcranial Direct Current Stimulation Targeting the Supplementary Motor Area for the Treatment of Subacute Post-stroke Aphasia

A study testing transcranial direct current stimulation in people with Post-stroke Aphasia, run by The First Affiliated Hospital of Anhui Medical University at 1 site in China.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

This study aims to investigate the efficacy of transcranial direct current stimulation (tDCS) in patients with post-stroke aphasia (PSA) and to explore its potential neural mechanisms. The study will recruit PSA patients and provide them with 14 tDCS sessions over 7 days, along with speech therapy. Read more about this study

Who is it for?
Ages 18 to 80 years
Conditions the study is for
Post-stroke Aphasia
What is being tested?
transcranial direct current stimulation
Could I receive a placebo?
No, everyone receives an active treatment
How many people
40 participants
Where
1 siteChina
Study dates
30 Jul 2025to 31 Jan 2027
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 80 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Patients must be between 18 and 80 years of age
  • First stroke in the left hemisphere
  • Stroke onset within the past 12 weeks
  • Native Chinese speakers who were able to communicate normally prior to onset
  • Diagnosed with aphasia using the ABC scale
  • Right-handed
  • Informed consent obtained from the patient and family members

Who cannot join

  • Time since stroke onset exceeds 12 weeks
  • History of psychiatric or neurological disorders
  • History of surgery for severe head trauma, brain tumors, or brain abscesses
  • Severe articulation disorders
  • Claustrophobia or implants incompatible with MRI
  • Inability to cooperate with language scale testing or fMRI scanning
  • History of previous stroke

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

China1 site, 1 recruiting
  • transcranial direct current stimulation (tDCS)

    Hefei, Anhui

    Jian Guan, +86-19810696998, 1003935828@qq.com

    Recruiting

Other trials in China

About this study

Official title: Study on the Efficacy and Neural Mechanisms of Transcranial Direct Current Stimulation Targeting the Supplementary Motor Area for the Treatment of Subacute Post-stroke Aphasia

This study aims to investigate the efficacy of transcranial direct current stimulation (tDCS) in patients with post-stroke aphasia (PSA) and to explore its potential neural mechanisms. The study will recruit PSA patients and provide them with 14 tDCS sessions over 7 days, along with speech therapy. Language Behavior Scale scores and resting-state functional MRI scans will be collected before and after the intervention. In addition, a retrospective comparison will be conducted of language function and resting-state fMRI changes in a group of PSA patients who received only speech therapy; these patients did not undergo any physical intervention but received only speech therapy. Changes in Language Behavior Scale scores and functional connectivity (FC) before and after treatment in the speech therapy-only group will be analyzed and compared with those in the tDCS intervention group.

Keywords
post-stroke aphasia, supplementary motor area, transcranial direct current stimulation

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • transcranial direct current stimulationOther

    As a non-invasive brain stimulation technique, tDCS offers advantages such as convenience, safety, and low cost. Its mechanism of action involves regulating neuronal activity in the brain by applying a weak direct current to the scalp.

Study groups in NCT07700537
Study groupRoleWhat they receive
tDCS groupExperimentalPSA patients enrolled in the tDCS group received tDCS treatment twice daily for 7 consecutive days, along with 7 days of speech-language therapy. The current intensity was 2 mA, and each treatment session lasted 20 minutes.
Receives: Other: transcranial direct current stimulation
The speech-language therapy groupNo interventionThe speech-language therapy group received only 7 days of speech-language therapy.

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Aphasia quotient (AQ)

    The Aphasia Battery of Chinese (ABC) is a standardized Chinese adaptation of the Western Aphasia Battery (WAB). The Aphasia Quotient (AQ) is a composite score that reflects the overall severity of language impairment. The AQ score ranges from a minimum of 0 to a maximum of 100. Higher scores indicate better language function (i.e., less severe impairment).

    Measured: Baseline, immediately after all interventions have ended

Secondary outcomes (1)
  1. rs-fMRI

    Measured: Baseline, immediately after all interventions have ended

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted14 Jul 2026
  2. Study start30 Jul 2025
  3. Primary completion1 Jan 2027 (estimated)
  4. Study completion31 Jan 2027 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Non-randomised
Intervention model
Parallel groups
Masking
Single blind
Who is masked
Outcomes assessor
Enrolment
40 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07700537
Sponsor's protocol ID
AHMU-tDCS-PSA
Status last verified
Jul 2026
First submitted
8 Jul 2026
Last updated
17 Jul 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No: Individual participant data will not be shared with other researchers due to patient privacy protection and the limitations of the informed consent form.

Questions about this trial

What is this clinical trial studying?

A study testing transcranial direct current stimulation in people with Post-stroke Aphasia, run by The First Affiliated Hospital of Anhui Medical University at 1 site in China.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 7 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 17 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Jian Guan (+86-19810696998, 1003935828@qq.com), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Aphasia quotient (AQ) (time frame: Baseline, immediately after all interventions have ended). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 17 Jul 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in